CN

You Are Leaving Avistone's Website

You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.

Cancel Continue

ABOUT US

Beijing Avistone Biotechnology Co., Ltd.

Innovative Biopharmaceutical Company

Avistone is a commercial-stage innovative biopharmaceutical company, and is committed to delivering high-quality innovative drugs to oncology patients worldwide, enabling them to achieve a better quality of life.

For a decade, Avistone has been dedicated to first-in-class and best-in-class drugs, and has established a strong pipeline comprising multiple novel therapies, with several candidates in advanced global clinical development.

More >
  • Integrity
  • Accountability
  • Pragmatism
  • Cooperation

HISTORY

TO BECOME A TRUSTWORTHY BIOPHARMACEUTICAL COMPANY

More >

2012

• Beijing Pearl Biotechnology Co., Ltd. was established

2015

· Obtained IND approval for Vebreltinib, and the clinical trials were initiated

2016

·  Vebreltinib clinical research was selected for China's National 13th Five-Year Plan Major New Drug Innovation Program

2018

• Beijing Avistone Biotechnology Co., Ltd. was established

• The mechanism of action and phase I trial results of Vebreltinib in glioma were published in the international top medical journal Cell

• The precision treatment of the indication of Vebreltinib for gliomas was selected as one of the Top Ten Advances in Life Sciences in China in 2018 by the China Association for Science and Technology

2020

· Obtained IND approval for PLB1004 in China, and the clinical trials were initiated

2021

· Vebreltinib was granted with breakthrough therapy by CDE

· Completed over US$200 million in Series A funding from Vivo Capital, Bain Capital, and Primavera Capital

2022

· NDA proposal for Vebreltinib was accepted by CDE and granted as Priority Review

2023

· Vebreltinib's MET exon 14 skipping NSCLC related indication was approved in China

· Completed over $140 million in Series B funding from CS Capital, IDG Capital, Yanchuang Capital, Bain Capital and Cathy Capital

2024

· Vebreltinib's ZM fusion gene related GBM indication was approved in China

· The results of the key registration study of Vebreltinib in treating NSCLC were published in the international top medical journal Journal of Clinical Oncology (JCO)

· Two approved indications of Vebreltinib were included in the China's 2024 National Reimbursement Drug List

· Completed over $35 million Series B+ funding from Beijing Medical and Health Care Industry Investment Fund (Limited Partnership) and Beijing Daxing District Industrial Development Fund

2025

·  Vebreltinib's MET amplification related NSCLC indication was approved in China

· Andamertinib's NDA proposal for NSCLC related indication was accepted by CDE and granted as Priority Review in China

 

Drag the mouse to switch left and right

PRODUCT

It is the only MET inhibitor in China that has been approved for three indications (NSCLC and glioma)*, with two of the three included in China's 2024 National Reimbursement Drug List

Vebreltinib Enteric Capsules(万比锐®)

It is the only MET inhibitor in China that has been approved for three indications (NSCLC and glioma)*, with two of the three included in China's 2024 National Reimbursement Drug List

[Indications]
  • NSCLC

    NSCLC

    Indication 1: Vebreltinib Enteric Capsule is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.

    Indication 2: Vebreltinib Enteric Capsule is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition (MET) amplification.

  • Glioma

    Glioma

    Indication 3: Adult patients with IDH mutant astrocytoma (WHO grade 4) with the PTPRZ1-MET fusion who have experienced treatment failure in prior therapies or glioblastoma with LGG history.

*Till July of 2025

More >

PIPELINE

More >
  • Drug
  • Target
  • Indication
  • Preclinical
  • IND
  • Phase I
  • Phase II
  • Phase III
  • NDA
  • Approval
  • Rights
Vebreltinib (PLB1001)
  • MET Exon 14 Skipping
  • ZM Fusion Gene
  • MET Amplification
  • NSCLC
  • GBM
  • NSCLC
  • China
  • China
  • China
China
Andamertinib (PLB1004)
  • EGFR Exon 20 Insertion
  • NSCLC
  • USA
  • China
Global
Vebreltinib
+
Andamertinib
  • MET Amplification/Overexpression after EGFR-TKI Resistance
  • High MET Expression with EGFR Mutation
  • NSCLC
  • China
  • China
Vebreltinib (China)
Andamertinib (Global)
ANS01
  • 2nd Generation C-MET Dysfunction
  • NSCLC
  • USA
  • China
Global
ANS01
+
Andamertinib
  • EGFR mutation
  • NSCLC
  • Global
Global
ANS03
  • ROS1&NTRK
  • Solid Tumor
  • Global
Global
ANS05
  • HER 2 Mutation NSCLC
  • HER 2 Amplification BC & GC
  • Solid Tumor
  • Global
Global
ANS02
  • 4th Generation EGFR-TKI
  • Solid Tumor
  • Global
Global
ANS06
  • Non-public
  • Solid Tumor
  • Global
Global
ANS07
  • Non-public
  • Solid Tumor
  • Global
Global
ANS08
  • Non-public
  • Solid Tumor
  • Global
Global
ANS09
  • Non-public
  • Solid Tumor
  • Global
Global